Muscular dystrophy gene therapy - Transgene/Roche Madison

Drug Profile

Muscular dystrophy gene therapy - Transgene/Roche Madison

Alternative Names: Myodys; TG 5001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Association Francaise contre les Myopathies; Transgene
  • Developer Roche Madison; Transgene
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Muscular dystrophies
  • Discontinued Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Muscular-dystrophies in France (Parenteral)
  • 24 Oct 2011 Roche Madison has been acquired by Arrowhead Research Corporation
  • 15 Jun 2009 Clinical development is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top